A leading infectious disease expert and one of the nation’s foremost COVID-19 researchers has voiced deep concerns about the ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

According to the Alzheimer’s Association, today in America, 7 million people are living with the condition. It is believed ...

( The Hill) — The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness from ...

The halt was triggered by an “imbalance,” the FDA said, in cases of severe lower respiratory tract infections (LRTIs) in children in a phase 1 trial of two Moderna RSV vaccines. One of the ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus, or RSV, in adults 60 years and older, making it the country's first authorized mRNA-based ...

The European Commission on Friday approved Moderna's respiratory syncytial virus (RSV) vaccine for older adults—the first time the bloc has authorised an mRNA shot against a disease other than ...

The RSV jab was Moderna’s second approved product. Shares in the biotech fell after data showed that protection from its recently approved mRNA-based vaccine waned more quickly than rival jabs ...